KYNTRA BIO, INC.
KYNB$21M
Micro CapNASDAQPharmaceutical PreparationsBiotechnology🇺🇸North AmericaSAN FRANCISCO52 employees
Kyntra Bio, Inc. (formerly FibroGen, Inc.) is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
Drugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
KYNB News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FG-4592 | Phase 3 | Anemia | - | - |
Market-Implied Move
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply